Written by abinScience Scientific Content Team · Last updated: September 2026
This page addresses the most frequently asked questions we receive from CROs, biotech R&D teams, and bioanalytical labs developing immunogenicity assays for GLP-1-based therapeutics. For a complete walkthrough of ADA/PK assay design, format selection, and the full reagent table by drug, see our GLP-1 Receptor Agonist ADA & PK Detection Guide.
Can I Use the Same ADA Assay for Semaglutide and Liraglutide?
Not recommended. Because semaglutide and liraglutide differ in peptide sequence, linker chemistry, and fatty-acid modification (C-18 diacid for semaglutide vs. C-16 palmitoyl for liraglutide), ADA generated against one molecule may show incomplete or unpredictable cross-reactivity with the other.
In practice, this means you need drug-specific critical reagents for each program:
The same principle applies to multi-receptor agonists: tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/GCGR) have distinct peptide backbones and modification patterns. Note also that dulaglutide is an Fc-fusion protein with a substantially larger molecular weight than the peptide analogs, which affects assay format and signal characteristics. Always validate cross-reactivity of your positive control antibody before applying it to a different drug program.
Do I Need a Neutralizing Antibody (NAb) Assay for GLP-1 Drugs?
Confirmed ADA-positive samples are commonly evaluated for neutralizing activity when neutralization is clinically or mechanistically relevant to the immunogenicity risk assessment. The approach should be determined based on the drug's mechanism of action, development stage, assay feasibility, and regulatory strategy (Ref. 1, 2).
Two format options are available:
Cell-based reporter gene assay — Uses a GLP-1R/cAMP-driven reporter cell line. Cell-based assays are generally preferred when they appropriately reflect the drug's biological mechanism of action. NAb in the sample competes with drug for receptor binding, reducing reporter signal.
Competitive ligand-binding assay — Uses an ELISA format where NAb competes with labeled drug for binding to coated receptor. Ligand-binding assays may be appropriate when they adequately reflect the relevant neutralizing mechanism. abinScience offers pre-validated kits in this format:
| Drug |
NAb ELISA Kit |
Cat. No. |
| Tirzepatide |
Anti-Tirzepatide Neutralizing Antibody ELISA Kit |
AP899038 |
| Dulaglutide |
Anti-Dulaglutide Neutralizing Antibody ELISA Kit |
AW328038 |
The choice between cell-based and ligand-binding NAb assays depends on the drug's mechanism of action, development stage, assay feasibility, and regulatory strategy. These decisions are typically made in consultation with regulatory authorities and should be tailored to each drug program.
How Should I Set Up Positive Controls and Cut Points for GLP-1 ADA Assays?
The low positive control (LPC) is an important system suitability control used to demonstrate that the assay can reproducibly detect a low level of ADA near the assay decision threshold. The high positive control (HPC) provides a reference at a higher ADA concentration within the assay's working range.
LPC selection: Titrate the positive-control antibody (e.g., Anti-Semaglutide pAb, HP899014) across the assay working range in pooled drug-naïve matrix. Empirically select a low concentration that generates a reproducible positive response near the assay decision threshold across validation runs.
HPC selection: Select a higher positive-control concentration within the assay's working range that provides a robust positive response without approaching signal saturation.
Key parameters for cut point and control setup should be determined empirically for each assay:
| Parameter |
Recommended Approach |
| Screening cut point |
Establish statistically using an appropriate treatment-naïve sample panel (95th percentile for nominal 5% false-positive rate) |
| Cut-point sample panel |
FDA notes that approximately 50 individual treatment-naïve samples are generally used, evaluated across multiple analysts and days (Ref. 1) |
| Confirmatory cut point |
Derive statistically from treatment-naïve samples tested with and without drug competition — do not use a universal fixed inhibition percentage (Ref. 1) |
| LPC |
Empirically select a low ADA concentration that reproducibly generates a positive response near the screening cut point |
| HPC |
Select a higher positive-control level within the assay's working range, without approaching signal saturation |
| Positive-control antibody |
Select a well-characterized surrogate ADA with appropriate drug specificity and lot-to-lot reproducibility |
All of these parameters are assay-specific and depend on the platform, matrix, reagent affinity, labeling, minimum required dilution, and statistical methodology. Values established for one GLP-1 peptide analog (e.g., semaglutide) should not be assumed to apply to Fc-fusion therapeutics (e.g., dulaglutide) or to assays using different positive-control antibodies.
How Should I Use the Semaglutide-BSA Conjugate (HP899032) for Plate Coating?
Small peptide drugs like semaglutide (MW ~4.1 kDa) may adhere poorly to polystyrene ELISA plates compared to larger proteins. The Semaglutide-BSA Conjugate (HP899032) presents semaglutide epitopes on a BSA carrier that binds plates efficiently.
Suggested starting conditions (optimize for your specific assay):
| Parameter |
Starting Condition |
| Coating concentration |
1 – 5 μg/mL in carbonate/bicarbonate buffer, pH 9.6 |
| Coating volume |
100 μL/well |
| Incubation |
Overnight (16–18 h) at 4°C, or 2 h at 37°C |
| Blocking |
1% BSA or 3% skim milk in PBST, 1 h at RT (see caveat below) |
| Primary application |
Direct/indirect ELISA for ADA screening; anti-semaglutide antibody characterization |
Optimal coating concentration, incubation time, and blocking conditions will depend on plate chemistry, BSA conjugation ratio, sample matrix, and the detection antibody used. These starting conditions should be titrated and optimized during method development.
Important caveats:
• Carrier-related background: Because carrier proteins can introduce carrier-specific background, BSA-conjugated drug and BSA-containing blocking buffers should be evaluated carefully in ADA assays, particularly when testing biological matrices with potential anti-carrier reactivity. Consider using a non-BSA blocking reagent (e.g., casein) during method development as an orthogonal control (Ref. 5).
• Epitope presentation: Carrier conjugation can improve peptide immobilization but may alter epitope accessibility. Unconjugated drug or orthogonal coating strategies (e.g., streptavidin–biotin) should be evaluated head-to-head during development. If you are using streptavidin-coated plates with biotinylated semaglutide for a bridging ELISA, the BSA conjugate is not needed.
References
1. US FDA. Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection. Guidance for Industry. January 2019. FDA.gov
2. EMA. Guideline on Immunogenicity Assessment of Therapeutic Proteins (EMEA/CHMP/BWP/14327/2006 Rev 1). 2017.
3. Novo Nordisk. OZEMPIC® (semaglutide) injection prescribing information. Revised 2024. FDA.gov
4. Shankar G, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267–1281. DOI: 10.1016/j.jpba.2008.09.020
5. Wadhwa M, et al. Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. Biologicals. 2015;43(5):298–306.
6. US FDA. Immunogenicity Assessment for Therapeutic Protein Products. Guidance for Industry. August 2014. FDA.gov
Looking for the Full ADA/PK Assay Design Guide?
Our comprehensive guide covers bridging ELISA format selection, a consolidated reagent table for 8 GLP-1 drugs, and troubleshooting drug tolerance, confirmatory cut points, and matrix effects.
Read the Full Guide →
All products are for research use only (RUO). Not for diagnostic or therapeutic use.
中文
English
한국어
日本語
Español
Français
Русский
